Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq on parental and acquired resistant cells (AqR)

ABSTRACT: Parental and AqR cells were obtained at diferent time-points (Day1 and Day 18). Total RNA was extracted and submitted for RNA-seq. Differential expression was observed between parental and AqR cells. AqR cells were derived from parental cells by adding inhibitor (CAY10566) every 3 days until cells became resistant (at about 3 weeks).

ORGANISM(S): Homo sapiens

PROVIDER: GSE131005 | GEO | 2021/02/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

ATAC-seq on parental and acquired resistant cells (AqR)

Project description:Parental and AqR cells were obtained. DNA was purified and submited for sequencing. Differential chromatin accessiblity was observed. AqR cells were derived from parental cells by adding inhibitor (CAY10566) every 3 days until cells became resistant (at about 3 weeks).

2021-02-22 | GSE130638 | GEO

RNA-seq on parental and acquired resistant cells (AqR)

Project description:RNA-seq on parental and acquired resistant cells (AqR)

| PRJNA542273 | ENA

ATAC-seq on parental and acquired resistant cells (AqR)

Project description:ATAC-seq on parental and acquired resistant cells (AqR)

| PRJNA540849 | ENA

RockDove Parental Care

Project description:RockDove Parental Care

| PRJEB28684 | ENA

Gene expression analysis of parental cell lines and cell lines with acquired resistance to compound 3 (C03) and compound 7 (C07).

Project description:Cells were cultured for a period of six months in slowly escalating concentrations of two small molecules (Compound 3 and Compund 7) whose protein target was unknown. Over this six month period, the cells cultured in C03 and C07 became resistant to the differentiation and growth inhibitory effects of the the compounds. Total RNA was harvested for RNA-sequencing.

2016-10-01 | GSE84875 | GEO

A375 melanoma parental and persister cells

Project description:A375 melanoma parental and persister cells

| PRJNA566394 | ENA

Gene expression of A204 parental and acquired resistant cells treated with Pazopanib, Dasatinib, and Sunitinib.

Project description:Malignant rhadboid tumours (MRTs) are lethal paediatric cancers characterised by a deficiency in the SWI/SNF subunit SMARCB1. Here we employ an integrated molecular profiling and chemical biology approach to demonstrate that the receptor tyrosine kinases (RTKs) PDGFRα and FGFR1 are coactivated in MRT cells and that dual blockade of these receptors has synergistic efficacy. Gene expression analysis of the four cell lines in the presence of TKI showed that the resistant sublines clustered together with the untreated parental cells and confirmed that PDGFRA was among the most highly downregulated genes in the resistant cells.

2016-09-08 | GSE78864 | GEO

Genome variation profiling of A204 parental and acquired-resistance cells treated with Pazopanib, Dasatinib and Sunitinib

Project description:Malignant rhadboid tumors (MRTs) are lethal paediatric cancers characterised by a deficiency in the SWI/SNF subunit SMARCB1. Here we employ an integrated molecular profiling and chemical biology approach to demonstrate that the receptor tyrosine kinases (RTKs) PDGFRα and FGFR1 are coactivated in MRT cells and that dual blockade of these receptors has synergistic efficacy. Genome variation profiling of A204 parental and acquired resistance cell line

2016-09-23 | GSE87208 | GEO

Transcriptional response to the HSP70 inhibitor MAL3-101 in parental rhabdomyosarcoma cells and isogenic acquired-resistance lines.

Project description:We demonstrate that inhibition of HSP70 with MAL3-101 induces activation of the unfolded protein response, and that cells with acquired resistance upregulate a cytosolic HSP70 at the level of mRNA. Whole transcriptome sequencing was undertaken of parental or acquired-resistance RMS13 cells treated with either DMSO or 10 micromolar MAL3-101.

2016-05-15 | E-GEOD-80525 | biostudies-arrayexpress

shRNA RNA-seq from HepG2 (ENCSR431SXF)

Project description:RNA-seq on HepG2 cells treated with an shRNA knockdown against AQR. (AQR-BGHLV37-C) For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf

2021-06-15 | GSE177214 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data